L14-8
L14-8 is a potent ferroptosis inducer. L14-8 promotes PLK1 degradation via ubiquitination, increasing TP53 phosphorylation to enhance SAT1 transcription, thereby triggering ferroptosis and cancer cell death. L14-8 can be used for the study of advanced prostate cancer[1].
Product Specifications
UNSPSC
12352005
Target
Ferroptosis; MDM-2/p53; Polo-like Kinase (PLK)
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Endocrinology
Smiles
FC1=CC=C([C@@H](OC(C=C)=O)CC[C@@H]2[C@@H](C3=CC=C(OC(C=C)=O)C=C3)N(C4=CC=C(F)C=C4)C2=O)C=C1
Molecular Formula
C30H25F2NO5
Molecular Weight
517.52
References & Citations
[1]Zhang Y, et al. Ezetimibe Engineered L14-8 Suppresses Advanced Prostate Cancer by Activating PLK1/TP53-SAT1-Induced Ferroptosis. Adv Sci (Weinh) . 2025 Jun 19:e04192.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
E6468 96 Tests
Leucine-rich repeat transmembrane neuronal protein 4 (LRRTM4) Human ELISA Kit
Sign In for Pricing
View Details MT08657-01 100 mg
1,2,3,4-Tetra-O-benzoyl-D-glucuronide methyl ester
Sign In for Pricing
View Details